Condition: Non-small Cell Lung Cancer · Sponsor: Korea Institute of Oriental Medicine
This is a multicenter, open-label, randomized controlled clinical trial designed to evaluate the efficacy and safety of combination therapy with Bojungikki-tang(BJIKT) and pembrolizumab monotherapy in patients with advanced non-small cell lung cancer whose tumors express PD-L1 positive with no EGFR or ALK genomic tumor aberrations. Based on prior pre-clinical studies, the combination of Bojungikki-tang and immune checkpoint inhibitors (ICIs) can be expected to improve survival and enhance the therapeutic efficacy of ICIs by modulating the systemic tumor-immune environment. Therefore, this clinical trial aims to assess the efficacy and safety of the combined therapy with BJIKT and pembrolizumab and establish clinical evidence for an integrative cancer treatment strategy by examining the survival rate and immune status following combined ICI and BJIKT treatment.
This description comes directly from the study's public registry record.
Mi-Kyung Jeong, Ph.D · 042-868-9475 · oiny2000@kiom.re.kr
Eunbyul Cho · 042-869-2779 · eunbc@kiom.re.kr
Always discuss trial participation with your own doctor first.
| Hallym University Medical Center | Anyang-si, Gyeonggi-do, South Korea | Recruiting |
| Pusan National University Yangsan Hospital | Yangsan, Gyeongsangnam-do, South Korea | Recruiting |
| Kyung Hee University Hospital | Seoul, South Korea | Recruiting |
| Hanyang University Seoul Hospital | Seoul, South Korea | Recruiting |
| Samsung medical center | Seoul, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
| The catholic university of Korea Seoul Saint. Mary's hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06249854